/LBRX

LBRX Stock - LB Pharmaceuticals Inc Common Stock

Q: What is the analyst price target for LBRX?

Analyst price target information is not currently available for LBRX.

Q: What is LBRX's market cap?

Market capitalization information is not currently available for LBRX.

Healthcare|Biotechnology|NASDAQ

$21.07+6.95%

+$1.37 (+6.95%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+51.9%upside

Target: $32.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LBRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$23.15

52W Low$13.36

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-64,830,000	$-11,376,000	$-2,809,000
Net Income	$-63,102,000	$-6,275,000	$-14,348,000
Net Margin	N/A	N/A	N/A
EPS	$-17.83	$-1.77	$-4.05

Company Overview

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$46

Average Target

↑ 119.9% Upside

Now

$27

Low

$46

Average

$78

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 6th 2025	Stifel	Initiation	Buy	$27
October 6th 2025	Piper Sandler	Initiation	Overweight	$78
October 6th 2025	Leerink Partners	Initiation	Outperform	$34

Earnings History & Surprises

LBRX

Beat Rate

Last 1 quarters

Avg Surprise

-7.0%

EPS vs Estimate

Beats / Misses

0/1

Last 12 quarters

Latest EPS

$-0.61

Q4 2025

EPS Surprise History

Q4 25

-7.0%

$-0.61vs$-0.57

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 5, 2026	$-0.46	—	—	—
Q4 2025	Nov 6, 2025	$-0.57	$-0.61	-7.0%	✗ MISS

Frequently Asked Questions about LBRX

What is LBRX's current stock price?

LB Pharmaceuticals Inc Common Stock (LBRX) is currently trading at $21.07 per share. The stock has moved +6.95% today.

What is the analyst price target for LBRX?

The average analyst price target for LBRX is $32.00, based on 1 analyst.

What sector is LB Pharmaceuticals Inc Common Stock in?

LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is LBRX's market cap?

LB Pharmaceuticals Inc Common Stock has a market capitalization of $0.53 billion, making it a small-cap company.

Does LBRX pay dividends?

No, LB Pharmaceuticals Inc Common Stock does not currently pay a dividend to shareholders.